| 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. | |
| | |
MedLine Citation:
|
PMID: 7514439 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Fludarabine monophosphate and 2Chlorodeoxyadenosine are nucleoside analogues with activity against Waldenström macroglobulinemia. However, it is not clear whether prior exposure to one analogue precludes response to the other compound. PATIENTS AND METHODS: Fourteen patients with Waldenström's macroglobulinemia and prior exposure to fludarabine were treated with two courses of 2chlorodeoxyadenosine. RESULTS: Three out of four patients that had previously responded to fludarabine and were relapsing from unmaintained remission, achieved a partial response with 2chlorodeoxyadenosine therapy. However, only one out of 10 patients with disease resistant to fludarabine responded to 2chlorodeoxyadenosine. CONCLUSIONS: 2chlorodeoxyadenosine may be effective in patients with Waldenström macroglobulinemia sensitive to fludarabine. However, this compound has limited activity for patients with disease resistant to fludarabine. |
| | |
Authors:
|
M A Dimopoulos; D M Weber; H Kantarjian; M Keating; R Alexanian |
Related Documents
:
|
2332039 - Prognostic significance of secondary cytogenetic changes and nonspecific cross-reacting... 3345829 - Prognostic parameters in myelodysplastic syndromes: a multiple regression analysis. 8946929 - Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (all). analysis ... 6192899 - Red cell aplasia in myelofibrosis with myeloid metaplasia. a distinct functional and cl... 2581639 - 5q- chromosome in acute leukemia with lymphoid morphology and expression of myeloid mem... 14965169 - Hairy cell leukemia: an autopsy study. 23474249 - Peripheral hypertrophic subepithelial corneal degeneration: nomenclature, phenotypes, a... 15984659 - Study of the cerebral vascular doppler velocimetry and eeg in a group of 18 cases of al... 8414419 - An association between hypothyroidism and primary open-angle glaucoma. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 5 ISSN: 0923-7534 ISO Abbreviation: Ann. Oncol. Publication Date: 1994 Mar |
Date Detail:
|
Created Date: 1994-06-23 Completed Date: 1994-06-23 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 288-9 Citation Subset: IM |
Affiliation:
|
Department of Hematology, University of Texas, M.D. Anderson Cancer Center Houston. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antimetabolites, Antineoplastic / therapeutic use* Cladribine / adverse effects, therapeutic use* Drug Resistance Female Humans Male Middle Aged Recurrence Treatment Outcome Vidarabine Phosphate / analogs & derivatives*, therapeutic use Waldenstrom Macroglobulinemia / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 29984-33-6/Vidarabine Phosphate; 4291-63-8/Cladribine; 75607-67-9/fludarabine monophosphate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor recepto...
Next Document: Immunofluorescence analysis of B-1 cell ontogeny in the mouse.